Rivaroxaban Plus Aspirin in Obese and Overweight Pati COMPASS Trial

Journal of the American College of Cardiology

77, 511-525

DOI: 10.1016/j.jacc.2020.11.061

Citation Report

#	Article	IF	Citations
1	Dual Antithrombotic Therapy Targeting Residual Risk for Atherosclerotic Cardiovascular Disease: Does Body Mass Index Matter?. Journal of the American College of Cardiology, 2021, 77, 526-528.	12.0	0
2	All Fat Is Not Created Equal: The Problem of Defining Obesity in the Elderly. Journal of the American College of Cardiology, 2021, 77, 2756.	12.0	0
3	Reply: All Fat Is Not Created Equal: The Problem of Defining Obesity in the Elderly. Journal of the American College of Cardiology, 2021, 77, 2757.	12.0	0
4	Direct Oral Anticoagulants Combined With Antiplatelet Therapy in the Treatment of Coronary Heart Disease: An Updated Meta-Analysis. Drugs, 2021, 81, 2003-2016.	15.5	7
5	COMPASS Study Results as a Foundation for New Treatment Approach for Neurological Patients. Opinion of the Expert Council of December 18, 2021. Zhurnal Nevrologii I Psikhiatrii Imeni S S Korsakova, 2022, 122, 94-99.	0.9	2
6	Anticoagulation and BMI: Effect of High Body Weight on the Safety and Efficacy of Direct Oral Anticoagulants. Future Cardiology, 2022, 18, 829-837.	1.2	2
7	Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index. JACC: Cardiovascular Interventions, 2022, 15, 1948-1960.	5.0	9
8	A Real-World Exploration Into Clinical Outcomes of Direct Oral Anticoagulant Dosing Regimens in Morbidly Obese Patients Using Data-Driven Approaches. American Journal of Cardiovascular Drugs, 2023, 23, 287-299.	3.7	3
9	EvidenceMap: A Three-Level Knowledge Representation for Medical Evidence Computation and Comprehension. Journal of the American Medical Informatics Association: JAMIA, 2023, 30, 1022-1031.	7.6	13
10	Low Dose Rivaroxaban for the Management of Atherosclerotic Cardiovascular Disease. Journal of Thrombosis and Thrombolysis, 2023, 56, 91-102.	2.2	9
11	Direct Oral Anticoagulants and the Risk of Adverse Clinical Outcomes Among Patients With Different Body Weight Categories: A Large Hospital-Based Study. European Journal of Clinical Pharmacology, 2024, 80, 1-11.	3.8	3
12	Update on Antithrombotic Therapy and Body Mass. A Clinical Consensus Statement of the ESC Working Group on Cardiovascular Pharmacotherapy and the ESC Working Group on Thrombosis. European Heart Journal - Cardiovascular Pharmacotherapy, 2024, 10, 614-645.	5.0	35
13	Atherosclerotic Features in Patients With Heart Failure. Archives of Medical Science, 2025, 21, 1107-1129.	2.4	7
14	Multidisciplinary Therapy to Target Obesity and Its Complications in Adult Population: A Narrative Review. Obesity Reviews, 2026, 27, e70093.	9.2	4
15	Anticoagulation in Peripheral Artery Disease: Scoping Review With ❄SAIMSARA. , 2026, .		0
16	Thrombo-Inflammation in Cardiometabolic Disease. Canadian Journal of Cardiology, 2026, 42, 1861-1871.	3.8	3
17	Specific Issues of Using Modern Anticoagulants for Prescribing Thromboembolic Complications During Surgical Interventions. Âkutskij Medicinskij žurnal, 2026, .	0.1	0